However, due to the expression of the majority of these targets (e.g., CD33, CD123) on normal hematopoietic cells, AML-redirected CAR T cells may only serve as a bridge to hematopoietic cell transplant (HCT). Here, CD33 is linked to acute myeloid leukemia.